Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 08:04   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this

  Be the first to like this.
 


 

8160 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 EOX 3.250.00 
 EPHE 38.080.00 
 ENZL 39.880.00 
 CRESW 0.010.00 
 AMSGP 109.300.00 
 ESXB 4.400.00 
 ALTL 35.420.00 
 STRZB 30.380.00 
 IRDMB 347.750.00 
 RWV 55.220.00 
Partners & Brokers